MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.
Read more at globenewswire.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
ALTERITY THERAPEUTICS-ADR
NASDAQ:ATHE (2/5/2025, 8:00:00 PM)
After market: 3.93 -0.32 (-7.53%)4.25
-0.26 (-5.76%)
ATHE Latest News and Analysis
16 hours ago - ChartmillWondering what's happening in today's after-hours session?Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
